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REVIEW ARTICLE
Guideline for the management of COVID-19 patients during hospital admission
in a non-intensive care setting
Klaus Nielsen Jeschkea, Barbara Bonnesen b, Ejvind Frausing Hansena, Jens-Ulrik Stæhr Jensenb,
Therese Sophie Lapperrec, Ulla Møller Weinreich d and Ole Hilberge
aDepartment of Pulmonary Medicine, Copenhagen University Hospital, Hvidovre, Denmark; bDepartment of Internal Medicine, Respiratory
Medicine Section, Herlev-Gentofte Hospital, Hellerup, Denmark; cDepartment of Pulmonary Medicine, Bispebjerg Hospital, Copenhagen,
Denmark; dDepartment of Respiratory Diseases, Aalborg University Hospital and the Clinical Institute, Aalborg University, Aalborg, Denmark;
eDepartment of Medicine, Vejle Hospital, Vejle, Denmark
ABSTRACT
Introduction: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has presented
health-care systems worldwide with novel challenges and experiences and evidence is emerging
during the pandemic. Patients requiring hospitalization frequently suffer from respiratory failure
of different severities.
Aim: The aim of this guideline is the treatment of patients with SARS CoV-2 (COVID-19) in
hospital; in particular, it addresses the treatment of respiratory failure treated in general
Internal Medical- and Pulmonary Medical wards.
Results: Elderly patients and patients with chronic disease are particularly vulnerable to COVID-
19. Target oxygen saturation should be between 92% and 96% in patients without chronic lung
diseases. Treatment with >5 L oxygen/min should be in close collaboration with intensive care
colleagues and >15 l/min preferably in intensive care units. High-flow nasal canula (HFNC) and
long-term Continuous Positive Airway Pressure (CPAP) are recommended for patients not
responding to conventional oxygen therapy. Non-invasive ventilation (NIV) is only recommended
for selected patients, such as those with a ceiling of treatment or patients presenting with
hypercapnic failure. With the use of humidification protective equipment as FFP2-3 masks should
be used. Nebulized medication should be avoided, and spacers should be used instead.
Conclusion: Respiratory failure is frequently the cause of hospitalization in patients with COVID-
19 and should be monitored closely.
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About this guideline
This guideline is made by a consultancy under the Danish
Society of Respiratory Medicine (DRSM) with the pur-
pose of providing an overview over COVID-19 disease
and its treatment during hospital admission in general
and respiratory wards that is hospital wards with exper-
tise in general Internal Medicine or specialized in
Pulmonary Medicine but does not cover Intensive Care
management of COVID-19. The guideline has a special
focus on respiratory care, particularly oxygen treatment
and respiratory support to guide hospital clinicians in
respiratory care for the patient in a non-intensive care
unit (ICU). For guidelines on intensive care therapy,
please consult the Surviving Sepsis Campaign [1].
In appendix 1 you will find a short pocket version,
especially aimed at junior doctors, with a focus on the
work in the emergency department.
Definition and prevalence
COVID-19 disease is caused by a pulmonary infection
with the new coronavirus, severe acute respiratory
infection coronavirus 2 (SARS-CoV-2). The virus
was first identified during an outbreak of severe
respiratory infections in December 2019 in the large
Chinese city, Wuhan. The new coronavirus SARS-
CoV-2 resembles SARS-CoV and MERS-CoV but has
never previously been identified in humans. The virus
is transmitted by droplets contact with contaminated
surfaces. For SARS-CoV-2 the reproductive value, R0,
is around 2.2 according to WHO (R0 is an indication
of the transmissibility of a virus, representing the
average number of new infections generated by an
infectious person in a totally naïve population). The
incubation period 2–14 days. Amongst those who con-
tracted COVID-19, 15–20% require hospitalization,
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with around 15% of cases presenting with severe
symptoms and 5% requiring intensive care [2]. ICU
mortality differs between studies but seems to be
around 26% [3]. The overall Case Fatality Rate (CFR)
is around 4% but differs significantly between popula-
tions [4].
The most frequent symptoms are fever, dry or pro-
ductive cough, fatigue and myalgia. Less frequent symp-
toms are cephalalgia, diarrhoea and, with disease
progression, dyspnea and respiratory failure, which may
even be tardive. Symptoms vary greatly amongst patients
and may not be present at admission, e.g. fever is only
seen in approximately half of the hospitalized patients.
Symptoms are summarized in Figure 1. Especially
patients with chronic diseases as well as patients on
immunosuppressive treatment regimens should be mon-
itored closely, please consult paragraph 11.
Diagnostics
The diagnosis of COVID-19 with new coronavirus
SARS-CoV-2 is obtained by a Reverse Transcription
Polymerase Chain Reaction (RT-PCR) analysis of
a pharyngeal swab. Hospitalized patients should be
monitored, from arrival at the hospital with Early
Warning Score (vitals including blood pressure, pulse
rate, respiratory rate, oxygen saturation, temperature
and responsiveness score) and a thorough physical
examination must be performed. The following para-
clinical tests are recommended:
● Blood tests:
○ Electrolytes and renal parameters
○ CRP and white blood cell count and differential
○ Ferritin






○ Arterial blood gas analysis in patients with
signs of respiratory insufficiency or dyspnea
● Chest X-ray
● ECG
● Microbiological samples of sputum, urine and
blood, as appropriate.
ProBNP and Troponin-T/I may be considered but
should be requested in accordance with local
recommendations.
● Pharyngeal swab for coronavirus (note: First swab
may be negative). If the patient is still suspected of
COVID-19, isolation should be maintained, and
PCR repeated after 24 h. As the pharyngeal swab
may be a false negative, tracheal suctioning may
be considered if the patient has a productive
cough.
Consider
● Pharyngeal swab for Influenza A/B and RS virus
PCR
● Pharyngeal swab for Mycoplasma/Chlamydia
PCR
It is recommended that diagnostic samples are
obtained at initial contact with the patient and before
the patient is moved to the general ward. Depending
Figure 1. Summary of Risk factors, symptoms, paraclinical findings, and complications in COVID-19; in red: Most frequent; in yellow:
Less frequent.
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on the condition of the patient and diagnostic results
other investigative measures may be considered:
● Bronchoscopy should only be performed in
exceptional cases and only for differential diag-
nostic purposes.
● Pleuracentesis, in case of pleural effusion, should
be carried out bedside to avoid the risk of
contamination.
The diagnostic work-up is summarized in Figure 2.
Radiological modalities
Chest X-ray should be performed in all patients
admitted with suspicion of COVID-19. Chest CT is
rarely indicated in the initial phase of the disease unless
other pathology, requiring CT, is suspected. Focused
lung ultrasound and general lung ultrasound (F-LUS/
LUS) is useful to monitor disease progression and to
diagnose complications at the bedside with minimal
exposure of disease to fellow patients and health-care
personnel.
Chest X-ray
Chest X-ray may be normal despite symptoms requir-
ing hospitalization. Typical radiological changes are
diffuse infiltrates. Rapidly progressive radiological
changes are associated with poor prognosis and the
extent of the radiological changes also is negatively
associated with prognosis [5].
CT scan
Even patients with minimal symptoms may display
multiple radiological changes on chest CT. In a study
from Wuhan, China, it was demonstrated that patho-
logical findings could be found in all pulmonary lobes,
with a tendency towards the right lower lobe being
more frequently involved. Bilateral changes were seen
in 79% of patients, 54% had peripheral ground glass
changes and 44% had diffuse changes. The most typical
findings were ground glass changes (65%), interlobular
septal thickening (35%), air-bronchograms (47%),
crazy paving (10%) and pleural thickening. Pleural
effusion was rare and only seen in 5% of patients [6].
Lung ultrasound (F-LUS/LUS)
Lung ultrasound is very useful in patients with
COVID-19. It may be used for radiological follow-up
and to acknowledge complications as consolidation,
atelectasis, pleural effusion, and pneumothorax [7].
A small Chinese study has investigated ultrasound
findings in patients with COVID-19 [8]. The most
frequent findings were 1) thickening of the pleura, 2)
B-lines in various patterns, amongst those; focal, multi-
ple and confluent 3) consolidations and air-
bronchograms and 4) regression of B-lines with
Figure 2. Summary of diagnostic workup for hospitalized COVID-19 patients.
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recovery and in continuation with this, dominant
A-line patterns.
Considerations about the extent of care
In all patients, and especially in those suspected of
COVID-19, the extent of care should be considered at
admission. A decision should be made by the admitting
doctor, and in case this is a junior doctor, a senior
doctor should be involved in the decision.
The choice of the ceiling of treatment has a great
impact on the choice of strategy for oxygenation
and respiratory support. In general, in patients
where health conditions allow intubation (Do
Intubate (DI) patients), with hypoxic respiratory
failure (type 1 respiratory failure), who do not
respond to oxygen therapy at moderate flow (up
to 15 l/min) referral to the Intensive Care Unit
(ICU) should be considered. The ICU doctor should
be advised about patients with clinical signs of dis-
ease progression and progressive respiratory failure,
requiring ≥5 L of oxygen/minute. If the patient has
been considered a candidate for intubation, patients
with hypercapnic respiratory failure (type 2 respira-
tory failure) and COPD should be intubated if the
patient does not respond sufficiently to non-
invasive ventilation (NIV).
Oxygen treatment and respiratory support
All units treating COVID-19 patients may be involved
in treatment with oxygen and respiratory support.
A compromised diffusion capacity and development
of ventilation-perfusion-mismatches, as a result of pro-
gressively affected lower airways, may lead to respira-
tory insufficiency and respiratory failure. In general,
four types of respiratory failure are described:
● Type 1 respiratory failure (hypoxic failure)
● Type 2 respiratory failure (hypercapnic failure)
● Type 3 respiratory failure (postoperatively)
● Type 4 respiratory failure (following hypo-
perfusion and circulatory failure)
The most frequent types of respiratory failure seen in
patients with COVID-19 in general wards will be type 1
and, to a lesser extent, type 2 or a combination of
those, and will, therefore, be discussed in detail below.
Hypoxic respiratory failure (type 1)
Oxygen/O2
To date, no evidence of optimal oxygen treatment for
COVID-19 patients is known, neither in terms of
a method for administration nor for target saturation
(SpO2).
Oxygen should be administered through
a conventional bi-nasal cannula or a high-flow nasal
cannula in patients with a need for a fraction of
inspired oxygen (FiO2) <40%. Humidification should
be avoided to minimize environmental aerosols and
thereby minimize the risk of spreading the disease.
With a need of FiO2 > 40% (equivalent to approx. 5
L/min on ordinary bi-nasal cannula), flow can be
increased, still without humidification, to 6 to 15 L/
min by using a high-flow nasal cannula, thus achieving
a FiO2 of approximately 40 to 60%. For achieving
higher FiO2, please consult the paragraph below on
high-flow nasal cannula (HFNC).
WHO recommends that in adult, non-pregnant
patients with COVID-19, target SpO2 should be >90%
when the patient is stabilized, while in critically ill
patients (with shock, coma, seizures, risk of respiratory
arrest), an SpO2 > 94% should be the target [9]. British
guidelines for acute oxygen treatment recommend that
in acute critically ill patients without risk of hypercap-
nia target SpO2 should be 94–98% [10]. A meta-
analysis from Lancet, including 16.037 patients,
demonstrated increased mortality in patients treated
with liberal oxygen treatment compared to conserva-
tive oxygen treatment, though most studies were based
on patients with acute cerebral- or coronary ischemia
[11]. Consistent results were seen in a smaller study in
480 ICU patients [12].
The Danish Health Authorities published National
recommendations for oxygen treatment of adult
patients in an acute setting, with a weak recommen-
dation of oxygen treatment targeted at SpO2 ≥ 94%
and a weak recommendation for titration of oxygen
to a target SpO2 between 94 and 98% for patients
with acute illness and an SpO2 < 94% [13]. A study
in patients with acute respiratory distress syndrome
(ARDS), randomized to intensive care and SpO2
88–92% versus SpO2 > 96%, indicated an increased
mortality at the lower SpO2 target, and the study was
terminated before enrolment was completed [14].
The Surviving Sepsis Campaign guidelines on
COVID-19 does not recommend SpO2 < 90%, nor
above 96%, and recommend target SpO2 between 92
and 96%. Patients with COPD and COVID-19
should be treated with oxygen, according to usual
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recommendations, with target SpO2 between 88 and
92% [15].
DSRM recommends:
-That target SpO2 in COVID-19 patients without
known chronic lung disease should be 92–96%
-That target SpO2 in COVID-19 patients with
known chronic lung disease (COPD) should be
88–92%
In patients with type 1 respiratory failure requiring
FiO2 > 40% an increase of oxygen flow to 6–15 L/min
is recommended. Flow in this range can be delivered
without humidification and by nasal cannula used for
high flow. Consider therapy with either continuous
CPAP or HFNC or oxygen via a mask with
a reservoir (Table 1). These treatment modalities are
considered equal.
If possible, oxygen humidification should be avoided
to reduce particle contamination in the environment.
Recommendations are shown in Table 2.
High-flow nasal cannula (HFNC)
HFNC treatment may, according to the WHO recom-
mendations, be considered in type 1 respiratory failure
in COVID-19 patients [9]. As such, HFNC may be
used both in DI-patients and patients not recom-
mended for intubation (Do Not Intubate (DNI)).
HFNC has previously been shown useful for milder
cases of ARDS, with less than one out of five patients in
need for treatment escalation to intubation [16].
During the COVID-19 pandemic, there have been con-
cerns about environmental particle distribution from
HFNC, but in a recent study particle distribution to the
environment has been shown to be less than for oxygen
treatment with 5 L/min on ordinary bi-nasal cannula,
even at an HFNC-flow of 60 L [17,18]. DRSM recom-
mends fitting the largest possible Optiflow™- cannula in
the individual patient.
For monitoring patients treated with HFNC the





respiratory rate [16]. A ROX index >4.88 indi-
cates a low risk of intubation, and thereby use of HFNC
can continue, whereas a ROX-index <2.85 should lead to
intubation if DI has been decided. At values in between
patients should be monitored closely [19]. The index was
used during the COVID-19 epidemic in Wuhan for
monitoring HFNC-treated patients (Figure 3) [20].
An example of a ROX-index calculation: SpO2: 90%,
FiO2: 0.70, RR: 30 ((90/0.7)/30) = ROX-index of 4.28.
FiO2 can be read from the display of the high-flow
device.
Ordinary-heated humidifiers may be used as an
alternative, should HFNC not be available, preferably
with an Optiflow™ nasal cannula. Please note that this
will generate considerably more aerosol distribution to
the surroundings and should be accompanied using
suitable protective equipment, i.e. FP2/FFP3 masks.
CPAP
Continuous Positive Airway Pressure (CPAP) may be
administered through different equipment at variable
pressures and duration. In principle, we distinguish
between intermittent CPAP (iCPAP) and continuous
CPAP (cCPAP). iCPAP may be administered using
single-patient use equipment or simple electric devices.
cCPAP should be administered through dedicated
CPAP-equipment or NIV-ventilators in CPAP-mode.
Evidence of the effect of iCPAP is modest as studies
are small and the methodology used is weak [21].
iCPAP may be used for the treatment of atelectasis
and mucus clearance; probably by improving collateral
ventilation [21]. iCPAP increases Functional Residual
capacity (FRC) and recruit alveoli; however, the effect
only lasts while iCPAP is applied to the patient and will
therefore only be modest if iCPAP only is used for
minutes, at hours’ interval.
cCPAP has been used as a home treatment of
obstructive sleep apnoea (OSA) and for manifest
heart failure, where it reduces mortality and need for
intubation equivalent to NIV. cCPAP increases FRC
and recruit alveoli; reduces dead space ventilation and
re-expand liquid-filled alveoli [22].
The WHO guideline for COVID-19 does not recom-
mend CPAP for adult patients with COVID-19 [9].
Surviving Sepsis Campaign recommends treatment
with high PEEP to patients with COVID-19 and
ARDS, which has proven superior to treatment with
low PEEP during mechanical ventilation of ARDS due
to other conditions [1]. As PEEP and CPAP physiolo-
gically have approximately the same effect; CPAP at
relatively high pressures (>10 cm H2O) should be con-
sidered [21].
The Italian guidelines for COVID-19 by the Italian
Thoracic Society and Italian Respiratory Society
recommend cCPAP at 10–12 cm H20, which may be
increased to 15–20 cm H2O in patients not responding
sufficiently to concomitant oxygen flows at 10–15
L [23]. cCPAP is often necessary continuously for
several days in patients with COVID-19. CPAP is pre-
ferably administered by ”helmet” to reduce the envir-
onmental spread of aerosols; however, experience with
this kind of treatment in Denmark is sparse, and thus
CPAP by mask must be applied with appropriate pre-
cautions for contamination (Table 3) [23].
EUROPEAN CLINICAL RESPIRATORY JOURNAL 5
Table 1. Flowchart for the treatment of type 1 respiratory failure and choice of protective
equipment.
Type1 respiratory failure. Target: All patients without chronic lung disease and COPD patients 
with PCO2<6.0kPa: SO2 92-96%. Patients with COPD and PCO2>6.0kPa: SO2 88-92%
:tnempiuqeevitcetorPylppusnegyxO
Include always eye shield 
Mild to moderate COVID-19: Target SpO2 obtainable with ≤ 5 L 
O2/min (FiO2 0.4), delivered by bi-nasal cannula 
Surgical mask. Working < 2 m 
of the patient: FFP2/3 
OpStegraT 2 not obtained  
Target SpO2 deniatbo
Severe COVID-19: Target SpO2 obtainable with 6-15 L O2/min 
(FiO2 0.4-0.6). Consider advising ICU-personnel about the 
patient’s condition. Use: 
Start/end/break: FFP3(FFP2) 
cCPAP, initially 10-12 cm H2O, may be increased 
In the room: Surgical mask 
In the room, < 2 meters from 
the patient: FFP2 
OR 
HFNC with Optiflow™: Initial flow 45 L/min + oxygen to meet SpO2
requirements.  
OR  
Oxygen by reservoir mask 
OpStegraT 2 not obtained  
Target SpO2 deniatboton




Consult ICU consultant: 
Continue HFNC at higher 
flow/higher FiO2 at IMU or ICU  
Continue HFNC at higher 
flow/higher FiO2 at IMU 
In the room: Surgical mask 
In the room, < 2 meters from 
the patient: FFP2OR Target SpO2 not obtained 
Intubate NIV, closed system, e.g. 6/16 
cm H20. Effect should be 
evaluated after i.e. 2 hours 
Table 2. Recommendations on humidification of oxygen delivery for patients suspected of- or diagnosed
with COVID-19.
Ordinary bi-nasal cannula, ≤5 litres O2/min No humidification
Optiflow™nasal cannula, 6–15 litres O2/min Preferably no humidification
Continuous CPAP and NIV No humidification
HFNC or, if not available, heated humidifier Always humidified
Figure 3. ROX-Score for evaluation of oxygen treatment of type 1 respiratory failure, treated with High-Flow treatment.
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In general, iCPAP cannot be expected to have any
major clinical effect on COVID-19 or ARDS and
should only be used in the context of its usual indica-
tion (atelectasis, mucus clearance). cCPAP has physio-
logically beneficial effects on gas exchange in patients
with COVID-19 and may be used in patients not
responding to oxygen therapy. Pressures of 10–12 cm
H2O or higher should be used. Please note that use of
cCPAP in a general ward requires close monitoring of
the patients, who should be awake and circulatory
stable. The effect of cCPAP should be noticeable imme-
diately with a decrease in respiratory rate and decrease
in required oxygen therapy; otherwise, ICU should be
consulted. If oxygen requirements should increase
again after they initially reduced, intubation should
also be considered. If the ward staff is inexperienced
in the use of cCPAP, treatment should take place in
ICU or equivalent experienced department.
BiPAP/NIV
Use of Bilevel Positive Airway Pressure/NIV for the
treatment of hypoxic failure in patients with COVID-
19 is poorly described, there are no randomized trials
to date. Previous studies have focused on the use of
NIV for viral pneumonias and hypoxic respiratory fail-
ure with reports on treatment failure rates of 30–33%
and in a more recent study on H1N1 influenza virus
infections, with treatment failure rates between 13 and
77% [24].
In general, the use of NIV for hypoxic failure should be
carried out in intermediate care units (IMU) or ICU
where intubation and mechanical ventilation is at hand.
NIV with an open circuit system is highly contaminating
the surrounding environment in terms of potential infec-
tive particles. Therefore, an anti-virus filter should be
used on the exhalation port, placed on the tube and not
on the mask (Figure 4). In DNI-patients NIV should be
considered in case of the inadequate effect of oxygen,
HFNC, and CPAP, but should be administered under
close monitoring and only at low tidal volumes
(4–8 mL/kg) [1].
Due to increased risk of particle contamination of
the environment, NIV should be used without humi-
dification in patients with COVID-19. Furthermore,
Table 3. Flowchart for treatment and choice of protective equipment in type 2 respiratory
failure.
Type 2 respiratory failure: Target saturation SpO2 88-92% 
Mild- moderate COVID-19: Target SpO2 obtainable with ≤ 5 
L O2/min (FiO2 0.4):
NIV according to guidelines, closed system Start/end/break: FFP3(FFP2) 
In the room: Surgical mask 
In the room, < 2 meters from the 
patient: FFP2
OpStegraT 2 not obtained  
Target SpO2 deniatbo
Severe COVID-19: Target SpO2 obtainable with 6-15 L 
O2/min (FiO2 0.4-0.6). Consider advising ICU-personnel 
about the patients’ condition. 
Start/end/break: FFP3(FFP2) 
In the room: Surgical mask 
In the room, < 2 meters from the 
patient: FFP2
Increase Oxygen Flow and /or Increase both EPAP and IPAP 
(Range between those ≥ 7 cm H2O) 
Target SO2 not obtained  
Very severe COVID-19: Target SpO2 obtainable with>15 L 
O2/min (FiO2 >0.6):
DI: DNI Start/end/break: FFP3(FFP2) 
In the room: Surgical mask 
In the room, < 2 meters from the 
patient: FFP2
Continue NIV at IMU or ICU 
Consider further changes in 
NIV. Consider palliative care 
OR 
Intubation
Figure 4. Closed system CPAP/NIV: Non-vented mask – filter – exhalation port – tube-filter ventilator.
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awareness of mask fitting is recommended to diminish
particle distribution to the environment.
In patients with COVID-19 using domiciliary NIV
humidification should not be used if home care is
provided to the patient.
In all other cases, NIV should be used according to
national guidelines. For type 2 respiratory failure,
please consult Table 3.
Hypercapnic respiratory failure (type 2)
Patients with COPD-developing exacerbation
(AECOPD) are at risk of developing hypercapnic
respiratory failure and respiratory acidosis. This should
be treated with NIV according to GOLD recommenda-
tions [15,25]. Patients with asthma and without diag-
nosed chronic lung disease may develop type 2
respiratory failure. This should be treated in ICU.
Nebulised medication
Particle contamination of the environment is consider-
able during the use of nebulized medication [26,27],
especially when administered through a mask [18].
However, also administration through a mouthpiece
causes substantial contamination, which may be
reduced using a particle filter [28].
Disease transmission through the use of nebulized
medication has been shown, both during outbreaks of
Influenza and SARS [29–31] and has also been sug-
gested in COVID-19 [32]. Therefore, the use of neb-
ulized medication, unless when administered through
a particle filter, is not recommended during the
COVID-19 epidemic [33].
The following systems may be used for administra-
tion of short-acting beta-2-agonist (SABA) and/or
short-acting muscarinic antagonists (SAMA) in
patients who are incapable of using usual inhalers:
Use of spacer with mask
Administration of inhaled SABA/SAMA is equal to
nebulization through mouthpiece, superior to nebuli-
zation through mash yet inferior to nebulization using
MESH-technology [34,35].
Use of spacer treatment requires minimal coopera-
tion from the patient. Consider the use of a spacer with
the mouthpiece in patients who can cooperate.
COVID-19 complications
A number of complications to SARS-CoV-2 disease
have been recognized so far [6,36,37], and different
patient categories have different susceptibilities. An
overview is given in Figure 1, and certain aspects,
such as bacterial complications and patients with
chronic diseases will be addressed in detail below.
Antimicrobial treatment
Antiviral treatments against Coronavirus
No specific antiviral agents have been developed
against COVID-19. Recently, in a randomized trial,
the combination Lopinavir–Ritonavir (protease inhibi-
tor + agent to increase bioavailability) has been inves-
tigated in 199 adult patients with severe COVID-19
respiratory infection, compared to standard care. After
28 days, there was no difference in mortality rate
between groups. Treatment is not recommended in
April 2020 [38]. Treatment with Hydroxychloroquine
as immune regulatory- and antiviral agent has been
suggested in COVID-19. Hydroxychloroquine has
been known since the 1930ʹies and is used as an anti-
inflammatory treatment of rheumatic diseases and for
prophylaxis and treatment of malaria, but also as an
anti-viral treatment of, e.g. Flavivirus, Retrovirus, and
Coronavirus, by an inhibitory effect on virus replica-
tion [39]. Hydrochloroquine has been well tolerated
even in long-term use and no teratogen effect has
been described. In vitro cell studies in primate cells
infected with the coronavirus SARS-1 indicated a dose-
respondent, inhibitory effect of hydrochloroquine [40].
There are ongoing studies investigating the effect of
hydroxychloroquine/chloroquine in COVID-19 dis-
ease [41,42]. Off label use of hydrochloroquine is
therefore not recommended.
Anti-bacterial agents
Antibacterial agents are of no use against viral infec-
tions; however, they are useful in the treatment of
suspected/verified secondary bacterial infections.
A previous study showed that 50% of patients who
died of COVID-19 had secondary infection, whereas
only 1% of patients who survived had had a secondary
infection (p < 0.0001) and septic shock was seen in
70%/0% in the respective groups [37]. There are no
solid data on which microorganisms are most prevalent
in secondary infections. However, it is reasonable to
believe that bacterial infections are most prevalent, and
variable within the patient population, co-dependent
on both pulmonary (e.g. bronchiectasis and COPD)
and other chronic comorbidities (e.g. diabetes, treat-
ment with immunosuppressants). As such, there is
reason to believe that secondary bacterial infections
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are important for disease development and the
patient’s prognosis.
It is therefore recommended that at any given time, at
admission or during hospitalization, if a secondary bac-
terial infection is suspected, antibiotic treatment should
be initiated. Treatment should be broad-spectrum, as
the most common aetiology of secondary infections in
COVID-19 is yet unknown, and since secondary infec-
tions are often caused by bacteria resistant to small-
spectrum antibiotics. The diagnostic work-up does not
differ from that in other patients; suspected bacterial
infection and relevant material for microbiological
investigation should be secured before the start of anti-
biotic treatment. The most frequent infection is prob-
ably pneumonia and it is unknown whether the
secondary bacterial pneumonias should be considered
equivalent to community-acquired pneumonia or hos-
pital-acquired pneumonia. Furthermore, disease pro-
gression in case of secondary bacterial infection has
been rapid. The empiric recommendation is therefore:
Pneumonia (suspected or confirmed)
Non-ICU with oxygen need ≤5 LO2/min and/or
FiO2 ≤ 0.4:
● Tolerant to beta-lactam antibiotics:
○ Inj. Piperacillin/Tazobactam 4 g + 0.5 g x 4 i.v. *
● Intolerant to beta-lactam antibiotics:
○ Inj. Cefuroxim 1.5 g x 3 i.v.
Treatment failure (2–3 days with no significant clinical
or para-clinical improvement):
● Inj. Meropenem 1 g x 3 i.v. *
* Dose dependence on renal function and body weight,
and should be corrected accordingly.
ICU-patients or oxygen need ≥5 LO2/min and/or
FiO2 ≥ 0.4
● Please consult the local recommendations for
antibiotic treatment in an ICU-setting
Treatment of Sepsis
Please consult the Surviving Sepsis campaign COVID-
19 guidelines [1]. Furthermore, a recent publication
includes a flow chart for handling critically ill patients
with COVID-19 [43].
Concerning septicemia and COVID-19, a publication
on the Coronavirus MERS showed that 20–25% of criti-
cally ill patients had bacterial co-infection [44].
In patients with parallel infections with other potent
viral agents, such as influenza, pulmonary secondary
bacterial infections with S. aureus have been shown to
be very prevalent and therefore this micro-organism
should be covered by the antibiotics of choice [45].
The most prevalent microorganisms cultured from
the lungs of septic patients in the ICU as secondary
agents have been K. pneumoniae, S. marscecens and
P. aeruginosa.
Other treatments – ARDS
A described complication to COVID-19 is Acute
Respiratory Distress Syndrome (ARDS). ARDS is
most frequently diagnosed by the so-called Berlin cri-
teria [46]:
● Bilateral ground-glass changes/opacities/
consolidations
● No other identified cause of these changes
● Severe type 1 respiratory Failure
● >7 days since primary insult
The condition is very difficult to treat, and patients are
treated in the ICU. A recent study indicated a possible
beneficial effect of dexamethasone [47]. However, this
is not recommended. A single RCT showed that prone
positioning of the patient has been shown to reduce
28 days-mortality from 33% to 16% (p < 0.0001) [48].
This modality has been used in the treatment of
patients with COVID-19 [49], however, results specific
to COVID-19-related ARDS are yet unknown.
Procalcitonin (PCT)
There are very few reports on initial PCT levels at
admission in patients with COVID-19 [50,51]. A low
PCT (<0.5 ng/ml) is seen in 95% of patients and med-
ian PCT is low 0.13 ng/ml, independent of oxygen
saturation. There are no systematic studies of sequen-
tial PCT measurements in patients with COVID-19,
and therefore it is unclear whether PCT would be of
use in early detection of secondary bacterial infections.
Previously, in vitro studies have shown that IFNγ is
inhibitory of the PCT response [52], which gives us
reason to hypothesize that infection with SARS-CoV-2
is inhibitory of a PCT response, even in case of sec-
ondary bacterial infection. Therefore, as of now, we do
not recommend neither initial nor sequential use of
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PCT measurements in hospitalized COVID-19
patients.
COVID-19 and comorbidities
Critical COVID-19 illness has been shown to be sig-
nificantly more prevalent in elderly and immunosup-
pressed patients, as well as those with comorbidities
[37]. In a recent, small study from Washington [53]
85% of patients had one or more comorbidities, which
is in line with previous studies [9,54,55]. Most preva-
lent were renal failure (48%), heart failure (42%),
COPD and diabetes (33%), and OSA (28%). It is also
noticeable that time-to-intubation among hospitalized
patients was only 1.5 days. It may both reflect pre-
hospital routines, but also reflect a significant vulner-
ability to the disease in patients with the above-
mentioned chronic diseases. It has been hypothesized
that a cause of the vulnerability was treatment with
ACE-inhibitors [56] as one of the virus-receptors’ is
ACE2 [57]; however, patients are, for now, not advised
to pause treatment. A retrospective study of fatal cases
in a population from Wuhan showed that 23% of
patients had renal failure and 29% had heart failure
[58]. It remains unclear whether patients with asthma
and allergies are at special risk, but Global Initiative for
Asthma recommends patients to be well treated at all
times [33]
Apart from respiratory comorbidities, special atten-
tion should, therefore, be paid to patients with:
● Cardiovascular comorbidities
● Renal comorbidities
● Diabetes (and obesity)
In patients with cardiovascular disease, special atten-
tion should be on progression in ischemic symptoms
and myocarditis, and in renal disease progression of
renal failure and acute renal failure. A thorough glu-
caemic control is recommended in diabetes and adjust-
ment in ventilatory requirements to meet the need of
the obese patients is essential.
Patients with respiratory comorbidities should continue
the usual treatment of their chronic respiratory diseases.
Isolation
Transmission of SARS-CoV-2 via aerosols and direct
contact is possible as the virus is viable in aerosols for
hours and on surfaces for days [59]. As such, there is
a risk of nosocomial disease transmission to other
patients and to health-care personnel. Therefore, the
patient suspected of COVID-19 should be isolated
from the moment of arrival at the Hospital.
A suitable distance between patients with sus-
pected- or confirmed SARS-CoV-2 is at least
1 meter [9]. In patients receiving different types of
oxygen therapy, protective equipment should be
taken within 2 meters of the patient. It is recom-
mended to use surgical masks for symptomatic
patients during the examination and during transpor-
tation, although the transportation of patients should
be minimized. Patients suspected of infection with
SARS-CoV-2 should be placed in a single isolation
room. When the diagnosis is confirmed, cohort iso-
lation is possible. Isolation can be terminated when
the patient has been asymptomatic for 48 h. However,
it has been suggested that a patient can transmit virus
more than 48 h after termination of symptoms and
contact to vulnerable subjects for a longer period
should be avoided until the matter has been clarified.
Hospital staff should be thoroughly instructed to
prevent infections, including the use of personal pro-
tective equipment [9,43]. The number of staff and the
number of procedures carried out in a ward with
SARS-CoV-2-infected patients should be limited; how-
ever, patient’s safety and well-being should not be
compromised.
Protective equipment
Standard precautions should always be used in all
health facilities whenever caring for a patient suspected
of- or diagnosed with COVID-19. These include hand
hygiene and use of personal protective equipment
when in direct- and indirect contact with patient’s
blood, body fluids, and secretions, as well as non-
intact skin [9].
Use of single use or dedicated equipment is pre-
ferred (i.e. stethoscopes, thermometer,s etc.). If the
equipment is shared between patients, it should be
cleaned and disinfected between use.
Protective equipment (mask, protective glasses,
gloves and long-sleeved, water-repellent single-use
coat) should be worn when entering the patient’s
room. Protective equipment should be removed before
leaving the patient’s room and thorough hand hygiene
should be carried out.
FFP3 or FFP2 masks are used during aerosol-
producing procedures, i.e. tracheal suction, intubation,
CPAP, NIV, HFNC, and bronchoscopy [60,61]. FFP2
masks and protective glasses are recommended when
working within 2 m of patients receiving ≤5 L oxygen
on bi-nasal cannula. Special care should be taken within
2 m of the patients using HFNC or CPAP/NIV due to
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the risk of environmental contamination with aerosols.
NIV with single tube systems may be used applying an
anti-viral filter to the exhalation port (Figure 4). In
addition, a filter is applied between the device and the
tube. The mask must be non-ventilated, and well fitted to
avoid air leak and aerosol spread. A number of studies
have demonstrated no disease transmission to health-
care personnel from patients treated with NIV if these
appropriate precautions were taken into account [62,63].
Recommendations for protective equipment in con-
nection with different oxygen treatment modalities are
resumed in Table 4.
Palliative care
Recommendations for palliative care for patients with
COVID-19 does not differ from recommendations in
general, we, therefore, recommend the use of local
guidelines or consult [64]. However, special care
should be taken of patients’ relatives who due to the
risk of spreading disease do not have the usual possi-
bilities for being with their loved ones.
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Appendix
DETERMINING THE MAXIMUM LEVEL OF CARE 
Needs to be determined by the admitting doctor, as 
COVID-19 can develop quickly. 
If the first assigned doctor is a junior doctor, the 
level of care should be consulted with the specialist 
in charge.
THE TREATMENT OF TYPE 1 RESPIRATORY 
FAILURE (HYPOXYA) 
TARGETS FOR TREATMENT WITH OXYGEN 
THERAPY  
With no known or suspected COPD: SO2 92-96% 
With known or suspected COPD: SO2 88-92% 
TREATMENT OF TYPE 2 RESPIRATORY FAILURE 
(HYPERKAPNIA)
OXYGEN THERAPY FOR PATIENTS WITH 
SUSPECTED OR VERIFIED INFECTION WITH 
SARS-CoV-2 
MONITORING HFNC THERAPY: 
An example of how to calculate the ROX-index: Sat 
0,98 (98%), FiO2, read from High Flow apparatus 0,5 
(50%), respiration frequency 40/min, equals a ROX-
index of 4,75 → Close monitoring for possible 
intubation.
ANTIBIOTICS
Bacterial coinfection seems to increase the 
mortality of COVID-19. Recommended antibiotics in 
case of bacterial co-infection: 
Piperacillin/Tazobactam 4g +0,5 g x 3 
Cefuroxim 1,5 g x 3, in case of allergy to penicillin. 
Meropenem 1 g x 3, in case of previous treatment 
failure. 
Remember to adjust the dosage of antibiotics in 
case of renal failure. 
ADDITIONAL TREATMENT 
It is important to optimize the treatment of all 
known comorbidities during COVID-19 disease. 
Oxygen 
treatment 
Treatment pathway Moisturizer 
0-5 L/min Conventional binasal catheter NO 
0-15 L /min Optiflow-catheter If possible, no 
15-60 L /min HFNC YES 
ROX-INDEX
≥4.88 Low risk of intubation
3,85-4.87 Close monitoring for possible intubation 
2,85-3.84 Monitoring in intensive care unit. High risk of 
intubation 
<2.85 Consider intubation
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MEDICAL IMAGING
Chest X-ray: Common findings are diffuse 
infiltrates; however normal chest X-rays can be 
seen. Extensive infiltrates which progress rapidly 
seem to be associated with a poor prognosis. 
CT only when concerned for complications. 
TTE in case of concerns for cardiac failure, 
myocardial infection, pericardial infection. 
OTHER PARACLINICAL TEST
ECG 
Bronchoscopy only for differential diagnosis. 
Pleuracentesis in case of pleural effusion. 
ADDITIONAL MICROBIOLOGY
Tracheal secretion / expectoration / throat swab 
examined by cultivation and resistance profiling, 
Influenza A and B, and test for atypical pneumonia. 
Blood cultivation and resistance profiling 
Urine analysis, cultivation and resistance profiling 
PRECAUTIONS AND PROTECTIVE EQUIPMENT
Nebulizers are not indicated due to risks of disease 
spreading. Medical safety glasses are recommend-
ed when working less than 2 meters distance to a 
patient receiving ≥ 5 L oxygen by nasal catheter. 
Oxygen by nasal catheter ≤5L Surgical mask
**
Oxygen by reservoir mask 6-15L Surgical mask
**
High Flow oxygen therapy Surgical mask
*
CPAP for secretion mobilization  FFP3/FFP2 mask 
CPAP/NIV open without filters FFP3/FFP2 mask 
CPAP/NIV closed with filters Surgical mask
**
Tracheal suction FFP3/FFP2 mask 
*
 At start-up, removal, pauses, patient handling, cough, 
use FFP3/FFP2 masks. 
**
 If within 2 m of the patient use FFP2 masks. 
CONTINOUS CPAP THERAPY 
If the patient is awake, hemodynamically stable and 
receives 5-10 L oxygen therapy you may start CPAP 
therapy. CPAP can be administered by a CPAP-
apparatus or a NIV-apparatus set to CPAP mode. 
CPAP should be administered continuously at a 
pressure of 10-12 cm H2O or more without 
humidification. Check algorithm for type 1 resp. 
failure. 
NIV THERAPY
Hypoxia without hypercapnia: Use the algorithm for 
respiratory failure type 1. May be initiated after 
failure of oxygen, HFNC and CPAP therapy. Use low 
tidal volumes (4-8 mL/kg) and monitor closely. 
Hypercapnia: Use the algorithm for respiratory 
failure type 2. 
Preferably NIV should be administered in  ICU or 
IMU, with particle filters, a well-fitted mask and 
without humidification to minimize leak and 
spreading of particles. 
COOPERATION WITH INTENSIVE CARE 
Please take into consideration the maximum level 
of care when consulting your ICU colleague. 
Consult your ICU colleague in case of:
Need for oxygen therapy ≥15 L/min. 
Rapid progression of need for oxygen therapy. 
At initiation of CPAP therapy. 
Failure of CPAP treatment (measured by increase in 
respiratory frequency, drop in saturation and need 
for oxygen therapy similar to before initiation of 
CPAP therapy. 
Respiratory failure type 2, known or suspected 
COPD, and indication for NIV therapy. 
COVID-19: National Guideline 
from the Danish Society 
of Respiratory Medicine 
DEFINITION AND PREVALENCE
COVID-19 is the clinical manifestation of disease 
caused by infection with SARS-CoV-2. It spreads by 
respiratory droplets. R0 is 2,2; the incubation time 
is approx. 5 days; approx. 14% develop disease 
severe enough to require admission; approx. 5% 
develop disease severe enough to require intensive 
care; and the mortality is expected to be 0,3 – 1%. 
Age, cardio-vascular and nephrological 
comorbidities, COPD, diabetes and overweight 
seems to increase the risk of severe disease. 
SYMPTOMS
Fever (probably only about half of patients), dry 
cough, fatigue, muscular pain, increased sputum, 
headache, dyspnoea (at progression), (diarrhoea).
DIAGNOSIS
SARS-CoV-2 RT-PCR-analysis of throat swab. The 
first sample can be negative. Can be repeated in 
case of suggestive anamnesis or clinical findings. 
Preferably by tracheal suction. 
BLOD SAMPLES
Medical admission profile and ferritin 
Troponin T/I and pro-BNP only for differential 
diagnostics. 
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